Table of Content

1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Rising Geriatric Population Across The Globe
3.2.2. Increasing Opportunities In The Developing Economies
3.2.3. Surge In The Prevalence Of Rheumatoid Arthritis Disease
3.2.4. Growing Healthcare Expenditure Across The Globe
3.3. Key Restraints
3.3.1. Patent Expirations
3.3.2. Lack Of Regulatory Guidelines For Biosimilars Will Delay Their Availability In Some Regions
3.3.3. Less Expensive Alternatives

4. Key Analytics
4.1. Porter’S Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Etiology Of Rheumatoid Arthritis (Ra)
4.3. Symptoms Of Rheumatoid Arthritis
4.4. Risk Factors Associated With Rheumatoid Arthritis
4.5. Opportunity Matrix
4.6. Vendor Landscape
4.7. Key Investment Insights

5. Market By Type
5.1. Prescription-Based Drugs
5.2. Over-The-Counter Drugs

6. Market By Drug Class
6.1. Disease Modifying Anti-Rheumatic Drugs
6.2. Nonsteroidal Anti-Inflammatory Drugs
6.3. Corticosteroids
6.4. Uric Acid Drugs
6.5. Other Drug Class

7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. The United Kingdom
7.2.2. France
7.2.3. Germany
7.2.4. Italy
7.2.5. Russia
7.2.6. Belgium
7.2.7. Poland
7.2.8. Rest Of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. Australia & New Zealand
7.3.5. South Korea
7.3.6. Thailand
7.3.7. Indonesia
7.3.8. Vietnam
7.3.9. Rest Of Asia Pacific
7.4. Rest Of World
7.4.1. Latin America
7.4.2. Middle East & Africa

8. Company Profiles
8.1. Abbott Laboratories
8.2. Abbvie Inc
8.3. Amgen Inc
8.4. Becton, Dickinson & Company (Bd)
8.5. Bio-Rad Laboratories Inc
8.6. Bristol-Myers Squibb Company
8.7. Eli Lilly & Company
8.8. Lupin Limited
8.9. F. Hoffmann-La Roche
8.10. Johnson & Johnson
8.11. Merck & Co Inc
8.12. Novartis Ag
8.13. Perkinelmer
8.14. Pfizer Inc
8.15. Ucb



List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: Global Anti-Rheumatics Market, By Type, In 2019
Figure 6: Global Anti-Rheumatics Market, By Prescription-Based Drugs, 2020-2028 (In $ Million)
Figure 7: Global Anti-Rheumatics Market, By Over-The-Counter Drugs, 2020-2028 (In $ Million)
Figure 8: Global Anti-Rheumatics Market, By Drug Class, In 2019
Figure 9: Global Anti-Rheumatics Market, By Disease Modifying Anti-Rheumatic Drugs, 2020-2028 (In $ Million)
Figure 10: Global Anti-Rheumatics Market, By Nonsteroidal Anti-Inflammatory Drugs, 2020-2028 (In $ Million)
Figure 11: Global Anti-Rheumatics Market, By Corticosteroids, 2020-2028 (In $ Million)
Figure 12: Global Anti-Rheumatics Market, By Uric Acid Drugs, 2020-2028 (In $ Million)
Figure 13: Global Anti-Rheumatics Market, By Other Drug Class, 2020-2028 (In $ Million)
Figure 14: North America Anti-Rheumatics Market, Country Outlook, 2019 & 2028 (In %)
Figure 15: The United States Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 16: Canada Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 17: Europe Anti-Rheumatics Market, Country Outlook, 2019 & 2028 (In %)
Figure 18: The United Kingdom Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 19: France Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 20: Germany Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 21: Italy Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 22: Russia Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 23: Belgium Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 24: Poland Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 25: Rest Of Europe Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 26: Asia Pacific Anti-Rheumatics Market, Country Outlook, 2019 & 2028 (In %)
Figure 27: China Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 28: Japan Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 29: India Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 30: Australia & New Zealand Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 31: South Korea Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 32: Thailand Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 33: Indonesia Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 34: Vietnam Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 35: Rest Of Asia Pacific Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 36: Rest Of World Anti-Rheumatics Market, Regional Outlook, 2019 & 2028 (In %)
Figure 37: Latin America Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 38: Middle East & Africa Anti-Rheumatics Market, 2020-2028 (In $ Million)


List of Tables


TABLE 1: MARKET SNAPSHOT - ANTI-RHEUMATICS
TABLE 2: COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS
TABLE 3: RISK FACTORS FOR RHEUMATOID ARTHRITIS
TABLE 4: GLOBAL ANTI-RHEUMATICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: GLOBAL ANTI-RHEUMATICS MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 6: GLOBAL PRESCRIPTION-BASED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: GLOBAL PRESCRIPTION-BASED DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 8: GLOBAL OVER-THE-COUNTER DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: GLOBAL OVER-THE-COUNTER DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: GLOBAL ANTI-RHEUMATICS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: GLOBAL ANTI-RHEUMATICS MARKET, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 12: GLOBAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: GLOBAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 15: GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 16: GLOBAL CORTICOSTEROIDS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: GLOBAL CORTICOSTEROIDS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: GLOBAL URIC ACID DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 19: GLOBAL URIC ACID DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 20: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 21: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 22: GLOBAL ANTI-RHEUMATICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 23: GLOBAL ANTI-RHEUMATICS MARKET, BY REGION MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 24: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 25: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY COUNTRY, FORECAST YEAR 2020-2028 (IN $ MILLION)
TABLE 26: EUROPE ANTI-RHEUMATICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 27: EUROPE ANTI-RHEUMATICS, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 28: ASIA PACIFIC ANTI-RHEUMATICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 29: ASIA PACIFIC ANTI-RHEUMATICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 30: REST OF WORLD ANTI-RHEUMATICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 31: REST OF WORLD ANTI-RHEUMATICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)